Multicenter expert recommendations on interventional valve-in-valve technology for mitral bioprosthetic valve destruction in China_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

 ZHANG Haibo ¹ , PAN Xiangbin ² , GUO Yingqiang ³ , WEI Lai ⁴ , YANG Jian ⁵ , ZHOU Daxin ⁶ , WU Yongjian ⁷ , MENG Xu ¹ , LIU Liming ⁸ , Chinese Research Hospital Association (CRHA) Heart Valve Disease Professional Committee , Asian Association for Heart Valve Disease (AAHVD) China Chapter

1. Valve Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, P. R. China;
2. Structural Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. China;
3. Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, P. R. China;
4. Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China;
5. Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, 710032, P. R. China;
6. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China;
7. Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P.R.China;
8. The Second Xiangya Hospital of Central South University, Changsha, 410011, P. R. China;

Corresponding author：

ZHANG Haibo, Email: zhanghb2318@163.com

Keywords：

Mitral bioprosthetic valve destruction; interventional valve-in-valve; expert recommendations

DOI：

10.7507/1007-4848.202406009

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Mitral valve replacement is one of the most common heart valve surgeries in China. In recent years, with the increase in degenerative valve diseases, older patients, and the progress of anti-calcification technology of biological valves, the proportion of mitral valve biological valve replacement has been increasing year by year. After the damage of traditional mitral valve biological valves, re-operation of valve replacement with thoracotomy is required. However, the adhesion between the heart and sternum, as well as the damage caused by cardiopulmonary bypass and cardiac arrest, can cause significant trauma to elderly patients and those with multiple organ dysfunction, leading to increased mortality and complication rates. In recent years, interventional valve surgery, especially transcatheter valve-in-valve surgery, has developed rapidly. This procedure can correct the damaged mitral valve function without stopping the heart, but there are still many differences between its technical process and conventional aortic valve replacement surgery. Therefore, organizing and writing multicenter expert recommendations on the technical process of transcatheter valve-in-valve surgery for damaged mitral valve biological valves is of great significance for the training and promotion of this technology.

Citation： ZHANG Haibo, PAN Xiangbin, GUO Yingqiang, WEI Lai, YANG Jian, ZHOU Daxin, WU Yongjian, MENG Xu, LIU Liming, Chinese Research Hospital Association (CRHA) Heart Valve Disease Professional Committee, Asian Association for Heart Valve Disease (AAHVD) China Chapter. Multicenter expert recommendations on interventional valve-in-valve technology for mitral bioprosthetic valve destruction in China. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(8): 1090-1095. doi: 10.7507/1007-4848.202406009 Copy

1.	Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med, 2011, 364(23): 2187-2198.
2.	Cheung A, Webb JG, Wong DR, et al. Transapical transcatheter mitral valve-in-valve implantation in a human. Ann Thorac Surg, 2009, 87(3): e18-e20.
3.	Elmariah S, Arzamendi D, Llanos A, et al. First experience with transcatheter valve-in-valve implantation for a stenotic mitral prosthesis within the United States. JACC Cardiovasc Interv, 2012, 5(5): e13-e14.
4.	Tada N, Enta Y, Sakurai M, et al. Transcatheter valve-in-valve implantation for failed mitral prosthesis: The first experience in Japan. Cardiovasc Interv Ther, 2017, 32(1): 82-86.
5.	Shivaraju A, Michel J, Frangieh AH, et al. Transcatheter aortic and mitral valve-in-valve implantation using the Edwards Sapien 3 Heart Valve. J Am Heart Assoc, 2018, 7(14): e007767.
6.	张海波, 孟旭, 王胜洵, 等. 二尖瓣生物瓣毁损的J-Valve介入瓣中瓣技术短期随访临床经验. 华西医学, 2020, 35(9): 1108-1112.Zhang HB, Meng X, Wang SX, et al. Transcatheter valve-in-valve implantation treatment for mitral bioprosthesis deterioration: Short-term follow-up. West China Med J, 2020, 35(9): 1108-1112.
7.	Yoon SH, Whisenant BK, Bleiziffer S, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J, 2019, 40(5): 441-451.
8.	Gallo M, Sá MPBO, Doulamis IP, et al. Transcatheter valve-in-valve implantation for degenerated bioprosthetic aortic and mitral valves - an update on indications, techniques, and clinical results. Expert Rev Med Devices, 2021, 18(7): 597-608.
9.	Harloff MT, Chowdhury M, Hirji SA, et al. A step-by-step guide to transseptal valve-in-valve transcatheter mitral valve replacement. Ann Cardiothorac Surg, 2021, 10(1): 113-121.
10.	You T, Wang W, Yi K, et al. Transcatheter mitral valve replacement for degenerated mitral valve bioprostheses, failure of mitral valvuloplasty and native valve with severe mitral annulus calcification:A systematic review and meta-analysis. J Cardiothorac Surg, 2021, 16(1): 293.
11.	Mankad SV, Aldea GS, Ho NM, et al. Transcatheter mitral valve implantation in degenerated bioprosthetic valves. J Am Soc Echocardiogr, 2018, 31(8): 845-859.
12.	Regueiro A, Granada JF, Dagenais F, et al. Transcatheter mitral valve replacement: Insights from early clinical experience and future challenges. J Am Coll Cardiol, 2017, 69(17): 2175-2192.
13.	Bapat VN, Attia R, Thomas M. Effect of valve design on the stent internal diameter of a bioprosthetic valve: A concept of true internal diameter and its implications for the valve-in-valve procedure. JACC Cardiovasc Interv, 2014, 7(2): 115-127.
14.	Rajani R, Attia R, Condemi F, et al. Multidetector computed tomography sizing of bioprosthetic valves: Guidelines for measurement and implications for valve-in-valve therapies. Clin Radiol, 2016, 71(1): e41-e48.
15.	Bapat VV, Khaliel F, Ihleberg L. Delayed migration of Sapien valve following a transcatheter mitral valve-in-valve implantation. Catheter Cardiovasc Interv, 2014, 83(1): e150-e154.
16.	Ye J. Transcatheter aortic valve replacement for isolated aortic regurgitation is coming! J Thorac Cardiovasc Surg, 2018, 156(1): 117-118.
17.	Ye J, Lee AJ, Blanke P, et al. The first transapical transcatheter aortic valve-in-valve implantation using the J-valve system into a failed biophysio aortic prosthesis in a patient with high risk of coronary obstruction. Catheter Cardiovasc Interv, 2018, 92(6): 1209-1214.
18.	Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(21): 2022.
19.	张怡, 熊恬园, 陈茂. 《2021 ESC/EACTS心脏瓣膜病管理指南》解读: 经导管瓣膜治疗策略的更新. 中国胸心血管外科临床志, 2021, 28(12): 1400-1408.Zhang Y, Xiong TY, Cheng M. Interpretation of 2021 ESC/EACTS guidelines for the management of valvular heart disease: Updated contents of the strategy of transcatheter therapy for valvular heart Disease. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(12): 1400-1408.

1. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med, 2011, 364(23): 2187-2198.
2. Cheung A, Webb JG, Wong DR, et al. Transapical transcatheter mitral valve-in-valve implantation in a human. Ann Thorac Surg, 2009, 87(3): e18-e20.
3. Elmariah S, Arzamendi D, Llanos A, et al. First experience with transcatheter valve-in-valve implantation for a stenotic mitral prosthesis within the United States. JACC Cardiovasc Interv, 2012, 5(5): e13-e14.
4. Tada N, Enta Y, Sakurai M, et al. Transcatheter valve-in-valve implantation for failed mitral prosthesis: The first experience in Japan. Cardiovasc Interv Ther, 2017, 32(1): 82-86.
5. Shivaraju A, Michel J, Frangieh AH, et al. Transcatheter aortic and mitral valve-in-valve implantation using the Edwards Sapien 3 Heart Valve. J Am Heart Assoc, 2018, 7(14): e007767.
6. 张海波, 孟旭, 王胜洵, 等. 二尖瓣生物瓣毁损的J-Valve介入瓣中瓣技术短期随访临床经验. 华西医学, 2020, 35(9): 1108-1112.Zhang HB, Meng X, Wang SX, et al. Transcatheter valve-in-valve implantation treatment for mitral bioprosthesis deterioration: Short-term follow-up. West China Med J, 2020, 35(9): 1108-1112.
7. Yoon SH, Whisenant BK, Bleiziffer S, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J, 2019, 40(5): 441-451.
8. Gallo M, Sá MPBO, Doulamis IP, et al. Transcatheter valve-in-valve implantation for degenerated bioprosthetic aortic and mitral valves - an update on indications, techniques, and clinical results. Expert Rev Med Devices, 2021, 18(7): 597-608.
9. Harloff MT, Chowdhury M, Hirji SA, et al. A step-by-step guide to transseptal valve-in-valve transcatheter mitral valve replacement. Ann Cardiothorac Surg, 2021, 10(1): 113-121.
10. You T, Wang W, Yi K, et al. Transcatheter mitral valve replacement for degenerated mitral valve bioprostheses, failure of mitral valvuloplasty and native valve with severe mitral annulus calcification:A systematic review and meta-analysis. J Cardiothorac Surg, 2021, 16(1): 293.
11. Mankad SV, Aldea GS, Ho NM, et al. Transcatheter mitral valve implantation in degenerated bioprosthetic valves. J Am Soc Echocardiogr, 2018, 31(8): 845-859.
12. Regueiro A, Granada JF, Dagenais F, et al. Transcatheter mitral valve replacement: Insights from early clinical experience and future challenges. J Am Coll Cardiol, 2017, 69(17): 2175-2192.
13. Bapat VN, Attia R, Thomas M. Effect of valve design on the stent internal diameter of a bioprosthetic valve: A concept of true internal diameter and its implications for the valve-in-valve procedure. JACC Cardiovasc Interv, 2014, 7(2): 115-127.
14. Rajani R, Attia R, Condemi F, et al. Multidetector computed tomography sizing of bioprosthetic valves: Guidelines for measurement and implications for valve-in-valve therapies. Clin Radiol, 2016, 71(1): e41-e48.
15. Bapat VV, Khaliel F, Ihleberg L. Delayed migration of Sapien valve following a transcatheter mitral valve-in-valve implantation. Catheter Cardiovasc Interv, 2014, 83(1): e150-e154.
16. Ye J. Transcatheter aortic valve replacement for isolated aortic regurgitation is coming! J Thorac Cardiovasc Surg, 2018, 156(1): 117-118.
17. Ye J, Lee AJ, Blanke P, et al. The first transapical transcatheter aortic valve-in-valve implantation using the J-valve system into a failed biophysio aortic prosthesis in a patient with high risk of coronary obstruction. Catheter Cardiovasc Interv, 2018, 92(6): 1209-1214.
18. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(21): 2022.
19. 张怡, 熊恬园, 陈茂. 《2021 ESC/EACTS心脏瓣膜病管理指南》解读: 经导管瓣膜治疗策略的更新. 中国胸心血管外科临床志, 2021, 28(12): 1400-1408.Zhang Y, Xiong TY, Cheng M. Interpretation of 2021 ESC/EACTS guidelines for the management of valvular heart disease: Updated contents of the strategy of transcatheter therapy for valvular heart Disease. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(12): 1400-1408.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Multicenter expert recommendations on interventional valve-in-valve technology for mitral bioprosthetic valve destruction in China

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content